Which patient groups were sapropterin trials primarily on?

Which patient groups were sapropterin trials primarily on?

Sapropterin (a synthetic form of tetrahydrobiopterin, BH4) was primarily studied in trials involving people with phenylketonuria (PKU), including both children and adults, because sapropterin’s use is based on its ability to help some patients convert phenylalanine more effectively.

Many sapropterin studies focused specifically on patients with “BH4-responsive” PKU (often described in trial results as “responsive” or “treatment-responsive”), since those are the patients most likely to show meaningful reductions in blood phenylalanine with BH4 therapy.

Were non-PKU groups studied too?

Sapropterin’s clinical development centered on PKU (including BH4-responsive and related PKU phenotypes). Trial populations were not primarily drawn from unrelated conditions; the main patient group across the sapropterin evidence base was PKU and related hyperphenylalaninemia, particularly where BH4 responsiveness was relevant.